HWM
KYMR icon

Hemington Wealth Management’s Kymera Therapeutics KYMR Stock Holding History

Hemington Wealth Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$0 Buy
+6
New +$271 ﹤0.01% 1637
2025
Q2 		– Sell
-1
Closed – – 1622
2025
Q1 		$0 Buy
+1
New +$36 ﹤0.01% 1635

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Hemington Wealth Management's KYMR Position: Q3 2025 in Review

Hemington Wealth Management opened a new position in Kymera Therapeutics (KYMR) in Q3 2025: 6 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1637 among its holdings. This is a return to the name: Hemington Wealth Management previously reported a position in KYMR as recently as Q1 2025.

Hemington Wealth Management first reported a position in KYMR in Q1 2025 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Hemington Wealth Management held 6 shares of Kymera Therapeutics worth $0 as of Q3 2025.
  • Kymera Therapeutics was a new Hemington Wealth Management position in Q3 2025.
  • Kymera Therapeutics made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1637 holding.
  • Hemington Wealth Management first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.